
## Mohammad Madjid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5104775/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
2	Potential Effects of Coronaviruses on the Cardiovascular System. JAMA Cardiology, 2020, 5, 831.	6.1	1,469
3	The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovascular Pathology, 2020, 48, 107233.	1.6	331
4	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
5	Influenza and Cardiovascular Disease. Circulation, 2003, 108, 2730-2736.	1.6	152
6	Regional, Artery-Specific Thresholds of Quantitative Myocardial Perfusion by PET Associated with Reduced Myocardial Infarction and Death After Revascularization in Stable Coronary Artery Disease. Journal of Nuclear Medicine, 2019, 60, 410-417.	5.0	83
7	Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators. American Journal of Cardiology, 2019, 124, 44-50.	1.6	42
8	Mortality Prediction by Quantitative PET Perfusion Expressed as Coronary Flow Capacity With and Without Revascularization. JACC: Cardiovascular Imaging, 2021, 14, 1020-1034.	5.3	41
9	Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty. Circulation, 2020, 141, 1667-1669.	1.6	16
10	Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity. European Heart Journal Cardiovascular Imaging, 2019, 20, 751-762.	1.2	15
11	Complications in Patients With COVID-19—Reply. JAMA Cardiology, 2021, 6, 360.	6.1	12
12	Combined LDL and VLDL Electronegativity Correlates with Coronary Heart Disease Risk in Asymptomatic Individuals. Journal of Clinical Medicine, 2019, 8, 1193.	2.4	10
13	Trends and Impact of the Use of Mechanical Circulatory Support for Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy. American Journal of Cardiology, 2021, 139, 28-33.	1.6	8
14	High prevalence of cholesterol-rich atherosclerotic lesions in ancient mummies: A near-infrared spectroscopy study. American Heart Journal, 2019, 216, 113-116.	2.7	6
15	Improvement of left ventricular function with surgical revascularization in patients eligible for implantable cardioverterâ€defibrillator. Journal of Cardiovascular Electrophysiology, 2022, 33, 244-251.	1.7	3
16	Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). American Heart Journal, 2021, 237, 135-146.	2.7	2
17	An attempt to reconcile the contrasting results of analyses on implantable cardioverter-defibrillator shocks during the pandemic. European Heart Journal, 2021, , .	2.2	1
18	Highlights of late-breaking clinical trials from the 2005 Scientific Sessions of the American Heart Association. Future Cardiology, 2006, 2, 161-164.	1.2	0